Physician profile
Ankit N Mehta
NPI 1295944346
$1,123,040.10
in general payments reported to CMS, 2019-2025
34 companies · $217K in 2025
The $217K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $25K · 2021: $70K · 2022: $263K · 2023: $297K · 2024: $224K · 2025: $217K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $552K · Consulting Fee: $91K · Travel and Lodging: $77K · Food and Beverage: $14K · Honoraria: $4,538 · Education: $21.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $551,548.00 |
| Consulting Fee | $90,514.83 |
| Travel and Lodging | $77,290.50 |
| Food and Beverage | $14,191.05 |
| Honoraria | $4,537.50 |
| Education | $21.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $436,221.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $375,844.61 | 2021-2025 | Farxiga, Lokelma, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $145,018.91 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $48,455.42 | 2019-2020 | |
| Amgen INC. | $39,804.20 | 2024-2025 | Tavneos, Uplizna |
| Chiesi USA, INC. | $29,010.42 | 2020-2025 | Elfabrio |
| Pharmacosmos Therapeutics INC. | $20,739.88 | 2022 | |
| Glaxosmithkline, LLC. | $13,066.80 | 2022-2025 | Benlysta |
| Travere Therapeutics, INC. | $4,103.29 | 2023-2025 | Filspari |
| Exthera Medical Corporation | $3,250.00 | 2025 | |
| Lilly USA, LLC | $2,400.00 | 2022 | |
| Akebia Therapeutics INC | $2,312.04 | 2019-2024 | Vafseo |
| Alnylam Pharmaceuticals INC. | $1,646.61 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $217.81 | 2021 | |
| Fresenius USA Marketing, INC. | $192.97 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $162.61 | 2025 | Flowtriever |
| Depuy Synthes Products, INC. | $157.09 | 2023 | Velys |
| Sanofi US Services INC. | $139.31 | 2025 | |
| Novo Nordisk INC | $105.49 | 2022 | |
| Boston Scientific Corporation | $50.50 | 2025 | General - Embolics |
| Otsuka America Pharmaceutical, INC. | $25.98 | 2025 | Jynarque |
| Horizon Therapeutics Plc | $25.65 | 2023 | Krystexxa |
| La Jolla Pharmaceutical Company | $23.53 | 2020 | |
| Opko Pharmaceuticals, LLC | $17.99 | 2020 | |
| Genentech USA, INC. | $16.64 | 2019 | |
| Nxstage Medical, INC. | $16.23 | 2023 | Nxstage Cartridge Express |
| Ultragenyx Pharmaceutical INC. | $14.43 | 2023 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.